Ifidancitinib
- Generic Name
- Ifidancitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H18FN5O3
- CAS Number
- 1236667-40-5
- Unique Ingredient Identifier
- R105E71J13
- Background
Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis).
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03585296
- Locations
- 🇺🇸
Aclaris Investigator Site, Austin, Texas, United States
🇺🇸Aclaris Investigational Site, Portland, Oregon, United States
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
Phase 2
Completed
- Conditions
- Alopecia AreataAlopecia TotalisAlopecia Universalis
- Interventions
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT03551821
- Locations
- 🇺🇸
Aclaris Investigator Site, Boynton Beach, Florida, United States
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03495817
- Locations
- 🇺🇸
Aclaris Investigational Site, Austin, Texas, United States
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
Phase 2
Completed
- Conditions
- Alopecia Universalis (AU)Alopecia Totalis (AT)
- Interventions
- Drug: Vehicle
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03315689
- Locations
- 🇺🇸
Aclaris Investigational Site, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath